Dapagliflozin for kidney disease to improve heart structure
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 or older) and sign informed consent
- Have CKD based on kidney blood test results (eGFR in the allowed range) and/or high urine protein levels
- Be on stable blood-pressure kidney-protecting medicine (ACE inhibitor or ARB) at a steady dose for at least 4 weeks
- If you have type 2 diabetes, your diabetes medicines must be stable for over 30 days before screening
- If you can become pregnant, use approved birth control methods during the study and for 30 days after; or be postmenopausal/surgically sterile
- Understand and read Danish (study team language requirement)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests a medication called dapagliflozin to see if it can reduce inflammation and improve red blood cell and iron levels in people with type 2 diabetes and chronic kidney disease.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This trial tests a medication called dapagliflozin (often used in type 2 diabetes) to see if it can help protect the kidneys in people with type 1 diabetes who already have some signs of kidney damage. If it works, it could slow down further kidney decline.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether a medicine called dapagliflozin can improve heart function in people hospitalized with acute heart failure. It may help the heart pump more efficiently and improve recovery.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.